Related Experiment Video

Updated: Sep 30, 2026

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation

Paolo Golino1, Massimo Ragni, Giovanni Cimmino

  • 1Division of Cardiology, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy. golino@unina.it.

Cardiovascular Drug Reviews
|June 19, 2002
PubMed

Insights

Tissue factor pathway inhibitor (TFPI) regulates blood clotting by inhibiting key factors in the coagulation cascade. Lower TFPI levels in heart attack patients indicate its consumption, highlighting its role in thrombotic disorders and potential as a therapeutic target.

Area of Science:

  • Biochemistry
  • Hematology
  • Vascular Biology

Background:

  • Tissue factor pathway inhibitor (TFPI) is a Kunitz-type inhibitor regulating the extrinsic coagulation pathway.
  • TFPI acts via a unique two-step mechanism, inhibiting Factor Xa directly and then feedback-inhibiting the Factor VIIa/tissue factor complex.
  • Recent research focuses on TFPI's pathophysiological role in thrombotic disorders.

Purpose of the Study:

  • To elucidate the pathophysiological significance of TFPI in thrombotic disorders.
  • To investigate the role of circulating TFPI levels in modulating coagulation cascade activity.
  • To explore TFPI as a potential therapeutic target for thrombotic conditions.

Main Methods:

  • Review of existing literature on TFPI biochemistry and physiology.
  • Analysis of animal models demonstrating TFPI's role in thrombus formation.
  • Measurement of TFPI plasma levels in patients with acute myocardial infarction (AMI).
  • Evaluation of gene therapy with TFPI for preventing thrombosis.

Main Results:

  • Neutralization of TFPI activity in animal models restored thrombus formation inhibited by aspirin.
  • Significantly lower TFPI levels were observed in the coronary sinus compared to the aorta in AMI patients, suggesting consumption.
  • Arterial wall gene transfection with TFPI effectively prevented intravascular thrombus formation in experimental models.

Conclusions:

  • Circulating TFPI levels are critical in regulating the procoagulant activity of tissue factor.
  • TFPI plays a significant pathophysiological role in thrombotic disorders, particularly in conditions like AMI.
  • TFPI represents a promising target for novel therapeutic strategies aimed at treating and preventing thrombosis.

More Related Videos

Extracellular Vesicle Tissue Factor Activity Assay03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...